What is ABECMA? ABECMA (idecabtagene vicleucel) is a prescription medicine for the treatment of multiple myeloma in patients who have received at least three kinds of treatment regimens that have not worked or have stopped working. ABECMA is a medicine made from your own white blood cells; the cells are genetically modified to recognize and attack your multiple myeloma cells.

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.

Managing my multiple myeloma now so

I can help her start her next chapter

—that’s my plan after ABECMA®

Actor portrayal

Managing my multiple myeloma now so

I can help her start her next chapter

—that’s my plan after ABECMA®

Actor portrayal

In a clinical study of 30.9 months follow-up (median), people treated with ABECMA lived longer without the disease getting worse or passing away, 13.8 months vs 4.4 months with standard treatments.

*Median is the middle number in a group of numbers arranged from lowest to highest.

Here’s how ABECMA was studied

In an ABECMA clinical study, 386 people were randomly put into 1 of 2 treatment groups:

  • 254 people were treated with ABECMA
  • 132 people received standard treatment

Everyone in the study had previously received 2 to 4 treatments that had not worked or stopped working, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. People treated with ABECMA were followed up by their healthcare team at 30.9 months (median) to see how well they were responding to treatment.

Click on each tab to see study results.

People receiving ABECMA had 3x more time without multiple myeloma growing or spreading

Clinical trial results showing median progression-free survival with ABECMA® (idecabtagene vicleucel) is 13.3 months compared to 4.4 months on standard treatment Clinical trial results showing median progression-free survival with ABECMA® (idecabtagene vicleucel) is 13.3 months compared to 4.4 months on standard treatment

More people responded to treatment with ABECMA

Clinical trial results showing 71% of patients (181/254) responded to treatment with ABECMA® (idecabtagene vicleucel) compared to 42% of people (55/132) on standard treatment Clinical trial results showing 71% of patients (181/254) responded to treatment with ABECMA® (idecabtagene vicleucel) compared to 42% of people (55/132) on standard treatment

Overall response:

The percentage of people who responded to treatment.


Clinical trial results showing 39% of people (98/254) treated with ABECMA® (idecabtagene vicleucel) had a complete response compared to 5% of people (7/132) on standard treatment Clinical trial results showing 39% of people (98/254) treated with ABECMA® (idecabtagene vicleucel) had a complete response compared to 5% of people (7/132) on standard treatment

Complete response or better:

No signs of cancer were found in the body. It does not mean the multiple myeloma has been cured.

People responded to ABECMA for 16.6 months (median).

  • This is called duration of response and is the length of time cancer responded to treatment without growing or spreading

Individual results may vary.

Foot note Standard Treatments:Patients were followed for 30.9 months (median).

Foot note Standard Treatments:People who were given standard treatment got one of the following medication combinations: daratumumab, pomalidomide, dexamethasone (DPd); daratumumab, bortezomib, dexamethasone (DVd); ixazomib, lenalidomide, dexamethasone (IRd); carfilzomib, dexamethasone (Kd); or elotuzumab, pomalidomide, dexamethasone (EPd).

Foot note Median:Median is the middle number in a group of numbers arranged from lowest to highest.

Download helpful
resources

VIEW RESOURCES

Learn more about
receiving ABECMA

See the treatment process